Researchers identified KIF11, a motor protein involved in cell division, as a common target for both resveratrol and chloroquine in oral squamous cell carcinoma. The combination therapy significantly suppressed cancer cell proliferation, migration, and invasion while promoting two distinct cell death pathways: apoptosis and ferroptosis. Molecular docking confirmed both compounds bind directly to KIF11, with cellular thermal shift assays validating this interaction. This represents an intriguing example of drug repurposing, where chloroquine—originally an antimalarial—gains new utility when paired with the wine-derived polyphenol resveratrol. The dual-mechanism approach targeting both programmed cell death and iron-dependent ferroptosis could address cancer's notorious ability to evade single therapeutic pathways. However, the research relies heavily on cell culture and a single mouse model, limiting immediate clinical translation. KIF11's role as a mitotic kinesin makes it an appealing cancer target since rapidly dividing malignant cells depend heavily on proper chromosome segregation. While promising for oral cancer specifically, the broader applicability across cancer types remains unexplored. This work exemplifies how computational target prediction combined with experimental validation can unlock unexpected therapeutic combinations from existing pharmaceutical arsenals.